First Clinical Trial Patient Treated Utilizing the New ZENITH Fenestrated + Endovascular Graft
Last month, UTHealth Houston faculty led the first procedure conducted in the United States utilizing the ZENITH® FENESTRATED+ Endovascular Graft (ZFEN+). Guided by the expertise of global investigator, Gustavo Oderich, MD, along with Naveed Saqib, MD, this milestone marks a significant advancement in the field.
The ZFEN+ clinical study, conducted under an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA), represents a pivotal moment in vascular treatment innovation. Designed to assess the safety and efficacy of ZFEN+ in conjunction with other investigational and commercially available graft systems, this study targets patients with specific anatomical criteria, including aortic aneurysms involving major visceral arteries such as juxtarenal, pararenal, and extent IV thoracoabdominal aneurysms.
As the medical community makes greater strides towards personalized solutions for complex abdominal and extent IV thoracoabdominal aneurysms with fenestrations, this patient-centered approach aims to optimize treatment outcomes by tailoring interventions to individual needs.
Congratulations to the vascular team for their work on this innovative study.